New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Zanubrutinib, Liso-Cel Data Highlight the Evolving Treatment Landscape in CLL

Zanubrutinib, Liso-Cel Data Highlight the Evolving Treatment Landscape in CLL

June 12, 2023Ryan ScottLuke J. Mountjoy, DO, discusses the implications of the SEQUOIA and the ALPINE trial, the importance of coming up with feasible and effective treatment options for patients with
World medicine November 21,2023
Zanubrutinib, Liso-Cel Data Highlight the Evolving Treatment Landscape in CLL

Zanubrutinib, Liso-Cel Data Highlight the Evolving Treatment Landscape in CLL

June 12, 2023Ryan ScottLuke J. Mountjoy, DO, discusses the implications of the SEQUOIA and the ALPINE trial, the importance of coming up with feasible and effective treatment options for patients with
World medicine November 21,2023
Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

At the 2023 American Society for Clinical Oncology Annual Meeting—to be held June 2-6 in Chicago, Illinois—Fred Hutchinson Cancer Center experts will present research spanning survivorship, advances i
Oncology November 21,2023
Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

At the 2023 American Society for Clinical Oncology Annual Meeting—to be held June 2-6 in Chicago, Illinois—Fred Hutchinson Cancer Center experts will present research spanning survivorship, advances i
Oncology November 21,2023
Expertise in cancer treatment could be used to find a cure for endometriosis

Expertise in cancer treatment could be used to find a cure for endometriosis

Endometriosis: If we utilize all the knowledge we have about cancer, there is reason to hope that effective diagnosis and treatments can be developed to combat the female condition 'everybody'
World medicine November 21,2023
Expertise in cancer treatment could be used to find a cure for endometriosis

Expertise in cancer treatment could be used to find a cure for endometriosis

Endometriosis: If we utilize all the knowledge we have about cancer, there is reason to hope that effective diagnosis and treatments can be developed to combat the female condition 'everybody'
World medicine November 21,2023
Navtemadlin Elicits Spleen Volume Reduction When Added to Stable Ruxolitinib in Patients With Myleofibrosis

Navtemadlin Elicits Spleen Volume Reduction When Added to Stable Ruxolitinib in Patients With Myleofibrosis

June 10, 2023Brittany LovelyPatients with primary or secondary TP53 wild-type myelofibrosis who experienced suboptimal response to ruxolitinib had clinically meaningful improvements in spleen volume r
World medicine November 21,2023
Navtemadlin Elicits Spleen Volume Reduction When Added to Stable Ruxolitinib in Patients With Myleofibrosis

Navtemadlin Elicits Spleen Volume Reduction When Added to Stable Ruxolitinib in Patients With Myleofibrosis

June 10, 2023Brittany LovelyPatients with primary or secondary TP53 wild-type myelofibrosis who experienced suboptimal response to ruxolitinib had clinically meaningful improvements in spleen volume r
World medicine November 21,2023
Innovative approach for detecting pre-cancerous lesions using large, high-res images

Innovative approach for detecting pre-cancerous lesions using large, high-res images

A new study presents an innovative approach to the crucial detection of pre-cancerous lesions using large, high-res images. A team of researchers from Portugal developed a machine learning solution th
World medicine November 21,2023
Innovative approach for detecting pre-cancerous lesions using large, high-res images

Innovative approach for detecting pre-cancerous lesions using large, high-res images

A new study presents an innovative approach to the crucial detection of pre-cancerous lesions using large, high-res images. A team of researchers from Portugal developed a machine learning solution th
World medicine November 21,2023
MD Anderson and Ochsner Health join forces to advance cancer care in Louisiana

MD Anderson and Ochsner Health join forces to advance cancer care in Louisiana

The University of Texas MD Anderson Cancer Center and New Orleans-based Ochsner Health today announced a partnership to create Ochsner MD Anderson Cancer Center in southeastern Louisiana. Cancer patie
World medicine November 21,2023
MD Anderson and Ochsner Health join forces to advance cancer care in Louisiana

MD Anderson and Ochsner Health join forces to advance cancer care in Louisiana

The University of Texas MD Anderson Cancer Center and New Orleans-based Ochsner Health today announced a partnership to create Ochsner MD Anderson Cancer Center in southeastern Louisiana. Cancer patie
World medicine November 21,2023
NCCN guidelines establish an equitable standard of care for cancer outcomes

NCCN guidelines establish an equitable standard of care for cancer outcomes

Today, the National Comprehensive Cancer Network®(NCCN®)-;an alliance of leading cancer centers-;convened a policy summit to examine how geography impacts cancer outcomes.NCCN Chief Executive Of
World medicine November 21,2023
NCCN guidelines establish an equitable standard of care for cancer outcomes

NCCN guidelines establish an equitable standard of care for cancer outcomes

Today, the National Comprehensive Cancer Network®(NCCN®)-;an alliance of leading cancer centers-;convened a policy summit to examine how geography impacts cancer outcomes.NCCN Chief Executive Of
World medicine November 21,2023
Sintilimab Plus Chemoradiotherapy Improves EFS in Locally Advanced Nasopharyngeal Carcinoma

Sintilimab Plus Chemoradiotherapy Improves EFS in Locally Advanced Nasopharyngeal Carcinoma

June 5, 2023Caroline SeymourThe addition of sintilimab to chemoradiotherapy demonstrated a significant reduction in the risk of disease recurrence or death, distant metastasis and locoregional recurre
World medicine November 21,2023
Sintilimab Plus Chemoradiotherapy Improves EFS in Locally Advanced Nasopharyngeal Carcinoma

Sintilimab Plus Chemoradiotherapy Improves EFS in Locally Advanced Nasopharyngeal Carcinoma

June 5, 2023Caroline SeymourThe addition of sintilimab to chemoradiotherapy demonstrated a significant reduction in the risk of disease recurrence or death, distant metastasis and locoregional recurre
World medicine November 21,2023
Historically redlined areas are less likely to be screened for breast, colorectal, and cervical cancer

Historically redlined areas are less likely to be screened for breast, colorectal, and cervical cancer

Although redlining was outlawed more than 50 years ago, new research shows that people today who live in historically redlined areas are less likely to be screened for breast, colorectal, and cervical
World medicine November 21,2023
Historically redlined areas are less likely to be screened for breast, colorectal, and cervical cancer

Historically redlined areas are less likely to be screened for breast, colorectal, and cervical cancer

Although redlining was outlawed more than 50 years ago, new research shows that people today who live in historically redlined areas are less likely to be screened for breast, colorectal, and cervical
World medicine November 21,2023
Domvanalimab-Based Combinations Generate Clinically Meaningful Responses in NSCLC

Domvanalimab-Based Combinations Generate Clinically Meaningful Responses in NSCLC

June 13, 2023Ashling WahnerThe combination of the TIGIT inhibitor domvanalimab and the A2R antagonist etrumadenant enhances the clinical activity of the PD-1 inhibitor zimberelimab when administered a
World medicine November 21,2023
Domvanalimab-Based Combinations Generate Clinically Meaningful Responses in NSCLC

Domvanalimab-Based Combinations Generate Clinically Meaningful Responses in NSCLC

June 13, 2023Ashling WahnerThe combination of the TIGIT inhibitor domvanalimab and the A2R antagonist etrumadenant enhances the clinical activity of the PD-1 inhibitor zimberelimab when administered a
World medicine November 21,2023
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com